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JAK2V617F mutational status and allele burden
have little influence on clinical phenotype and prog-
nosis in patients with post-polycythemia vera and
post-essential thrombocythemia myelofibrosis
The JAK2V617F mutational status and mutated allele
burden were evaluated in 65 patients with post-poly-
cythemia vera or post-essential thrombocythemia
myelofibrosis (PPV/PET-MF). All PPV-MF patients har-
bored the mutation as compared to 27% of PET-MF. The
V617F allele burden was higher in PPV- than in PET-MF
(72% vs. 50%); 78% of the patients had greater than
50% V617F allele burden, supporting an adverse role of
highest allele burden for MF transformation. In cases of
PET-MF, no meaningful difference between JAK2V617F
mutated and unmutated patients could be ascertained.
Patients in the highest quartile of V617F allele burden
were significantly older and had higher leukocyte and
CD34+ cell count in peripheral blood than those in lower
quartiles. There were 8 patients developing acute
myeloid leukemia, who were equally distributed among
JAK2V617F mutated or unmutated patients. We con-
clude that presence and burden of JAK2V617F mutation
provide little clinically relevant information in patients
with PPV/PET-MF.
Discovery of acquired recurrent molecular abnormali-
ties in JAK2 (JAK2V617F mutation in exon 14 or muta-
tions, insertions, deletions in exon 12) or MPL (mostly
MPLW515L/K) has improved the diagnostic approach to
the classic Philadelphia chromosome-negative chronic
myeloproliferative disorders, defined as myeloprolifera-
tive neoplasms (MPNs) in the upcoming revised WHO
classification.1 Virtually all patients with polycythemia
vera (PV) have a mutation in JAK2, which is represented
by the V617F allele in greater than 95% of cases; frequen-
cy of JAK2V617F mutation is 60-70% in patients with
essential thrombocythemia (ET) or primary myelofibrosis
(PMF), while 10% of PMF patients2 and up to 8% of
JAK2V617F unmutated ET3,4 patients harbor
MPLW515L/K mutation. Presence of these molecular
abnormalities constitutes a major diagnostic criteria in the
2008 WHO classification.1 A number of studies have
addressed the relevance of V617F mutational status and of
mutated allele burden on hematologic characteristics and
clinical presentation. In patients with PV or ET, the
amount of V617F allele measured in granulocytes was
found to be positively associated with hemoglobin level
and leukocyte count and inversely with platelet count;
furthermore, the higher the mutational burden, the high-
er the risk of presenting aquagenic pruritus, of developing
splenomegaly or suffering from cardiovascular events,
and of requiring cytotoxic therapy.5 In PMF, results have
been conflicting. An association of JAK2V617F mutation-
al status with poorer overall survival was reported by
Campbell et al.,6 but this has not been confirmed by oth-
ers.7,8 A greater risk of developing large splenomegaly and
leukemia was found in JAK2V617F mutated PMF patients
included in a large study,8 while conversely a better over-
all and leukemia-free survival for patients presenting the
highest V617F allele burden was reported in an analysis
from the Mayo Clinic.9
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On the other hand, information on patients with
post-polycythemia vera (PPV-MF) or post-essential
thrombocythemia myelofibrosis (PET-MF) is scanty,
and limited to a few small series. Passamonti et al.
found a significantly higher V617F allele burden in 16
patients with PPV-MF in comparison to both pre-
fibrotic and fully-fibrotic PMF patients,10 and allele
burden was correlated to the number of circulating
CD34+ cells. Tefferi et al. reported that patients with
PPV-MF were more frequently JAK2V617F mutated
than those with PET-MF (91% vs. 38.9%) and more
frequently had an allele burden greater than 50%
(found in 18% vs. 11.1% of the patients respectively).7
However, in these studies no attempt to correlate
genotype with hematologic or clinical characteristics
was made.
The aim of this study was to assess whether the
JAK2V617F mutational status and/or allele burden had
clinical and/or prognostic relevance for patients with
PPV/PET-MF. Sixty-five patients, 43 with PPV-MF and
22 with PET-MF, were included; the diagnosis of evo-
lution to MF from a pre-existing PV or ET was retro-
spectively verified in order to satisfy the recently
adopted criteria from the IWG-MRT.11 Retrospective
evaluation of archived data was approved by the local
Ethical Committee. All patients had a stored DNA
sample from purified granulocytes collected within
nine months of the diagnosis of evolution to MF;
analysis of JAK2V617F mutational status and mutated
allele burden was performed as described.12
The median time elapsed from original diagnosis of
PV or ET to myelofibrosis was 112 months (range 30-
317) for PPV-MF and 137 months (29-266) for PET/MF.
Median follow-up from the diagnosis of myelofibrosis
evolution was 39 months for the whole cohort of
patients, and it was not dissimilar for PPV-MF (40
months, range 6-275) and PET-MF (39 months, range
10-165) patients. During this period, 7 out of 8 patients
in whom acute myeloid leukemia (AML) developed
died at a median of 26 months (range 1-40) after
leukemia diagnosis. Mean survival from diagnosis of
myelofibrosis was 96 months (95% CI, 81-111) for the
entire cohort of patients, and 99 months (95% CI, 83-
115) and 83 months (95 CI, 53-112) for PPV-MF and
PET-MF patients respectively.
The hematologic characteristics of the patients at
diagnosis are reported in Table 1. A total of 49 patients
(75.3%) harbored the JAK2V617F mutation. In agree-
ment with previous reports,7,10 100% of PPV-MF
patients were JAK2V617F mutated. On the contrary,
the frequency of JAK2V617F mutation was 27.2%
among PET-MF patients, significantly lower than that
observed in a control group of 260 ET patients from
our Institution (63.4%; p<0.01).13 This result argues for
a dominant role of genetic mechanisms other than
JAK2V617F in the MF transformation of ET. The medi-
an V617F allele burden in the entire population of
patients was 73% ranging from 10 to 100%. The medi-
an value of V617F allele burden in PPV-MF was 72.0%,
significantly higher than that observed in a group of
173 PV patients previously reported12 who showed a
mean allele burden of 52%, confirming a role for the
Table 1. Main hematologic characteristics of PPV/PET-MF patients at the time of diagnosis.
JAK2 WT JAK2V617F JAK2V617F allele burden
PPV-MF PET-MF 1-50% 51-75% 76-100%
Patient N. 16 49 11 14 24
PPV/PET-MF 0/16 43/0 0/6 8/3 13/1 22/2
Age, years, median (range) 62 (33-77) 62 (36-78) 59 (49-70) 52 (36-70) 64 (52-78) 67 (48-77)3
Gender, female/male 11/5 20/23 4/2 7/4 6/8 11/13
N. patients with previous 0/9 (0) 10/28 (36) 1/6 (17) 3/10 (33) 2/8 (25) 6/16 (37)
thrombosis history1 (%)
N. patients with previous 4/9 (44) 6/25 (24) 0/6 (0) 1/6 (17) 4/10 (40) 1/15 (7)
chemotherapy 1,2 (%)
JAK2V617F allele (%), median − 78 (10-100) 45 (24-100) 28 (10-50) 62 (51-73) 97 (78-100)
(range)
White blood cell count 10.1 (5.0-53.9) 12 (3.4-48.9) 9.0 (2.5-15.5) 9.4 (2.5-17.2) 11.8 (6.2-48.9) 13 (4.4-47.7)3
(×109/L,) median (range)
Hemoglobin (g/dL), 11.9 (8.8-14.9) 14.2 (8.6-18) 12.0 (8.5-14.7) 13.9 (8.5-18) 13.6 (11-15.9) 13.5 (8.6-16.3)
median (range)
Platelet count (×109/L), 722 (136-1,538) 408 (102-1,500) 496 (87-904) 337 (87-900) 384 (102-641) 541 (140-1,500)
median (range)
N. patients with 2/9 (22) 2/33 (6) 0/6 (0) 1/11 1/14 0/14
PB blasts >1%1 (%)
LDH, U/L, median (range) 722 (426-1,723) 447 (223-1,500) 1,160 (745-1,525) 444 (240-1,525) 306 (223-859) 674 (286-1,500)
CD34+ cell count (%), 0.98 (0-6.95) 0.19 (0.01-4.1) 1.0 (0.02-7.0) 1.3 (0.02-7) 0.12 (0.01-4.1) 0.36 (0.03-3.6) 
median (range)
CD34+ cell count, (×106/L), 102.7 (0.7-2,000) 59.7 (1.4-3,000) 160.8 (2.1-417) 7.6 (3.3-417) 48 (1.4-309) 98 (3.1-3,000)3
median (range)
1Referred to the number of patients for whom the information was available. 2all patients treated with chemotherapy had received hydroxyurea alone or in
association/sequence with busulphan; no patient had received interferon. 3p<0.05 according to Spearman’s rank test.
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accumulation of mutated alleles in MF transformation
of PV. Finally, in PET-MF the median allele burden was
57%, a value significantly greater than the 26% of a
control group of ET patients from our Institution.13 This
result suggests that accumulation of mutant V617F alle-
les is also a mechanism of evolution toward MF in
JAK2V617F mutated ET patients.
Apart from a significantly lower platelet count
(p=0.04) in JAK2V617F mutated patients, no other
meaningful correlation with JAK2V617F mutational
status could be ascertained (Table 1). The V617F mutat-
ed or unmutated patients were also comparable in
terms of spleen size, incidence of thrombosis, inci-
dence of major hemorrhages (2 patients in each group,
all from previous ET), and the rate of AML transforma-
tion which occurred in 2/16 JAK2 unmutated and 6/49
JAK2V617F mutated patients (12.5% and 12.2%
respectively) (data not shown). The correlation between
V617F allele burden and clinical presentation and prog-
nosis was also studied by dividing patients into quar-
tiles of V617F allele distribution. We grouped together
the first two quartiles because of the low number of
patients included (Table 1), and we found that V617F
allele burden was positively correlated with age, white
blood cell count and circulating CD34+ cell count (all
with a p value <0.05). However, there was no statisti-
cally significant correlation with clinical characteristics,
i.e. spleen size, thrombosis, hemorrhages, nor with the
rate of patients who evolved to AML (3 of whom were
in the two first quartiles, one and 2 in the third and
fourth quartile respectively). 
To the best of our knowledge, this is the first study
specifically addressing the clinical relevance of
JAK2V617F mutation in patients who evolved to MF
from a previous PV or ET. The data presented herein
prompted us to conclude that neither the JAK2V617F
mutational status nor the V617F allele burden seem to
have relevance for disease phenotype or prognosis in
this setting of patients. However, the relatively short
follow-up might have prevented the discovery of corre-
lations of JAK2V617F mutational status with clinical
events occurring late in the history of these disorders,
in particular for the evolution to AML. This will require
larger patient series with a much longer observation.
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High-dose therapy and autologous stem cell trans-
plantation versus conventional therapy for
patients with advanced Hodgkin’s lymphoma
responding to front-line therapy: long-term results
The inclusion of high-dose therapy/autologous stem
cell transplantation (HDT/ASCT) in the initial treatment
plan for patients with unfavorable Hodgkin’s lymphoma
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